Case studies
Working with our customers to reduce time to market, deliver on quality, provide deep therapeutic expertise, and enhance R&D ROI.
Highlights
We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.
Proactive patient retention strategy in a GLP-1 RA trial
Explore how 91黑料 successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.
A small biotech success story
A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.
FSP partnership - sustained efficiency and ongoing innovation
The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.
By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.
All case studies
Select amongst our broad range of solutions and experience.
Line of therapy analysis to support commercialisation efforts of rare disease
Pulmonary arterial hypertension (PAH) often presents with vague symptoms, making diagnosis difficult and leading to frequent delays or misdiagnoses. While current treatments have improved outcomes, underserved populations with limited access to specialized care remain under treated.
Accelerating team growth to support client demand
This case study shows the effectiveness of this agile and forward-thinking approach to workforce scaling under time-
sensitive conditions.
sensitive conditions.
Privacy-safe, high-performing digital campaign targeting
Symphony Health, an 91黑料 plc company, and a trusted provider of healthcare data and analytics, collaborated with
Butler/Till to enhance the digital media buying strategy for a major pharmaceutical company.
Butler/Till to enhance the digital media buying strategy for a major pharmaceutical company.
Driving better outcomes with innovative interventions
A major pharmaceutical client explored whether a wellness app for glucose monitoring and nutrition coaching could reduce A1c levels in Type 2 Diabetes patients. They also assessed its potential to lower healthcare costs and its commercial viability for payer-supported integration into treatment plans.
Breakthrough patient reach
In Q1 2024, Underscore Marketing launched an innovative unbranded campaign to educate patients with a rare lung disease. Using advanced data and privacy-compliant methods, the initiative validated symptoms and introduced a soon-to-be FDA-approved treatment, setting a new benchmark for disease education in healthcare.
Symphony Health and dentsu health partner to reach rare disease patients
As a part of their ongoing Test & Learn strategy, dentsu health collaborated with several data partners to assess healthcare claims models and measure Audience Quality across two direct-to-consumer (DTC) display campaigns.
Scaling an optimised global vaccine trial with flexible FSP
91黑料 partnered with a leading pharma company to scale its global vaccine program using flexible, custom FSP solutions. By combining dedicated teams with on-demand support, 91黑料 helped expand trial reach, adapt to changing needs, and deliver nearly $10M in annual cost savings.
Partnering to provide vital regional support on a global medical device study
91黑料 was selected as a European partner CRO for a drug-coated balloon device study, supporting regulatory services, study start up and monitoring activities, and safety reporting service for study sites located across Europe. The device consequently received CE Mark certification and FDA approval.
Meeting new REMS SPL guidelines 22 months before they became mandatory
A CRO managing a Shared System REMS engaged 91黑料 Regulatory Consulting to support a Type V Drug Master File since 2016, covering four branded and 200 generic products. Following the FDA’s 2020 guidance on structured product labeling (SPL), 91黑料 prepared the REMS SPL to meet the December 2022 compliance deadline.
Enabling US and EU market entry for neurodegenerative disease treatment
An Asia Pacific based biotech was developing a therapeutic treatment for a neurodegenerative disorder. 91黑料 Regulatory Consulting was engaged to support market entry.
Ensuring consistent source data monitoring for a global cardiology study
This global, double-blind cardiology study evaluated an atrial shunt’s impact on quality of life and heart failure symptoms in 260 patients. Conducted over 4.5 years at 66 sites, it included a crossover option and five-year follow-up.
Collaborating to improve monitoring visit trip reports
A global, multi-centre trial is evaluating cardiac radioablation (CRA) vs. repeat catheter ablation for high-risk VT patients. Spanning 7.5 years, the study involves 380 randomized patients across 20+ sites in the U.S., U.K., and Germany.
Let's collaborate
Discover how 91黑料's expertise transforms clinical trials.